Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The pill and thrombosis: epidemiological considerations

C Carter1

  • 1Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Bailliere'S Clinical Obstetrics and Gynaecology
|March 7, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

ESMO open·2026
Same author

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Service evaluation of a new unscheduled paediatric dental service in Lothian, Scotland.

International journal of paediatric dentistry·2023
Same author

Moving the Needle Toward Fair Compensation in Pediatric Nephrology.

Frontiers in pediatrics·2022
Same author

Exploring the lived experience of women with rosacea: visible difference and psychological impact.

The British journal of dermatology·2021
Same author

Stress response after race and endurance training sessions and competitions in Arabian horses.

Preventive veterinary medicine·2021

Oral contraceptives increase thrombosis risk, but incidence is hard to estimate. Patient selection and genetic screening for thrombotic factors are key to safe use.

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Genetics

Background:

  • Oral contraceptives are widely used, but carry risks of venous and arterial thrombosis.
  • Estimating the precise incidence and attributable risk of thrombosis from oral contraceptives is challenging due to diagnostic and methodological limitations.
  • Previous pharmacological approaches to reduce thrombotic side-effects, like third-generation oral contraceptives, have been unsuccessful.

Purpose of the Study:

  • To highlight the difficulties in accurately assessing thrombosis risk associated with oral contraceptive use.
  • To emphasize the importance of patient selection and screening for thrombotic risk factors.
  • To explore the potential role of biochemical and genetic testing in managing oral contraceptive risks.

Main Methods:

Keywords:
BiologyBlood Coagulation EffectsContraceptionContraceptive Methods--administraction and dosageContraceptive Methods--pharmacodynamicsDiseasesEmbolismFamily PlanningFibrinolysisHematological EffectsHemic SystemLiterature ReviewOral Contraceptives, Combined--administraction and dosageOral Contraceptives, Combined--pharmacodynamicsOral Contraceptives--administraction and dosageOral Contraceptives--pharmacodynamicsPhysiologyRisk FactorsThromboembolismThrombosis--etiologyVascular Diseases

Related Experiment Videos

  • Review of existing literature on oral contraceptive-associated thrombosis.
  • Analysis of methodological challenges in epidemiological studies.
  • Discussion of pharmacological and non-pharmacological risk mitigation strategies.
  • Exploration of biochemical markers and genetic screening (e.g., Factor V Leiden).

    • Main Results:

    • Accurate incidence data for oral contraceptive-related thrombosis remain elusive.
    • Third-generation oral contraceptives have not significantly reduced venous thrombotic risk.
    • Cigarette smoking is confirmed as an adverse factor for arterial thrombosis in users.
    • Hypercoagulability testing and genetic screening show promise for patient selection.

    Conclusions:

    • Given the limitations of pharmacological interventions, careful patient selection is paramount.
    • Screening for prothrombotic abnormalities, such as Factor V Leiden genotype, can aid in identifying high-risk individuals.
    • Biochemical and genetic testing may represent future advancements in the safe prescription of oral contraceptives.